Get the Stockscreener App
2.01
1.47%
-0.03
Pre-market:
1.68
-0.33
-16.42%
Coherus Oncology Inc stock is traded at $2.01, with a volume of 838.18K.
It is down -1.47% in the last 24 hours and up +21.82% over the past month.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
See More
Previous Close:
$2.04
Open:
$2.06
24h Volume:
838.18K
Relative Volume:
0.45
Market Cap:
$242.95M
Revenue:
$257.24M
Net Income/Loss:
$-237.89M
P/E Ratio:
-0.7731
EPS:
-2.6
Net Cash Flow:
$-175.17M
1W Performance:
-3.83%
1M Performance:
+21.82%
6M Performance:
+119.46%
1Y Performance:
+79.46%
1-Day Range:
$1.975
$2.07
1-Week Range:
$1.945
$2.20
52-Week Range:
$0.71
$2.6158
Coherus Oncology Inc Stock (CHRS) Company Profile
Name
Coherus Oncology Inc
Sector
Industry
Phone
(650) 649-3530
Address
C/O DENNIS M. LANFEAR, REDWOOD CITY, CA
Compare CHRS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CHRS
Coherus Oncology Inc
|
2.01 | 246.58M | 257.24M | -237.89M | -175.17M | -2.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Coherus Oncology Inc Stock (CHRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-23-26 | Initiated | Oppenheimer | Outperform |
| Sep-04-25 | Upgrade | Maxim Group | Hold → Buy |
| Aug-16-24 | Downgrade | UBS | Buy → Neutral |
| Nov-17-23 | Initiated | Robert W. Baird | Outperform |
| Nov-08-23 | Downgrade | Maxim Group | Buy → Hold |
| Jul-24-23 | Initiated | Citigroup | Buy |
| May-01-23 | Initiated | Truist | Buy |
| Mar-28-23 | Upgrade | UBS | Neutral → Buy |
| Jun-14-22 | Initiated | UBS | Neutral |
| Mar-07-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-16-20 | Initiated | BofA Securities | Neutral |
| Apr-17-20 | Initiated | SunTrust | Buy |
| Aug-13-19 | Initiated | Mizuho | Buy |
| Aug-02-19 | Reiterated | H.C. Wainwright | Buy |
| Aug-02-19 | Reiterated | Maxim Group | Buy |
| Jun-11-19 | Initiated | Barclays | Overweight |
| May-07-19 | Initiated | H.C. Wainwright | Buy |
| Aug-28-18 | Initiated | H.C. Wainwright | Buy |
| Mar-09-18 | Reiterated | Maxim Group | Buy |
| Aug-08-17 | Reiterated | JP Morgan | Overweight |
| Jun-13-17 | Reiterated | Maxim Group | Buy |
| May-05-17 | Initiated | BMO Capital Markets | Outperform |
| Oct-19-16 | Initiated | Robert W. Baird | Outperform |
| Sep-07-16 | Initiated | Maxim Group | Buy |
| Jul-27-16 | Initiated | Citigroup | Buy |
| Jan-20-16 | Initiated | Credit Suisse | Outperform |
View All
Coherus Oncology Inc Stock (CHRS) Latest News
Coherus Prices $50.1 Mln Public Offering; Stock Plunges - Nasdaq
Coherus Oncology (CHRS) Launches $50.1M Public Offering - GuruFocus
Coherus Oncology prices stock offering to raise $50.1M - MSN
Coherus Oncology prices $50.1 million public offering of common stock By Investing.com - Investing.com India
Coherus Oncology Prices Public Offering at $1.75 per Share - Intellectia AI
Cancer-drug firm Coherus to raise $50M for LOQTORZI, clinical development - Stock Titan
Coherus Oncology announces pricing of public offering of common stock - marketscreener.com
Coherus Oncology Announces Pricing Of Public Offering Of Common Stock - TradingView
Press Release: Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock - 富途牛牛
Coherus Oncology announces proposed public offering of common stock - MSN
Coherus Oncology tumbles on planned equity offering - TradingView
Coherus BioSciences (CHRS) Announces Public Stock Offering - GuruFocus
Coherus Oncology, Inc. Announces Proposed Public Offering of Common Stock - The Manila Times
Coherus plans stock sale to fund LOQTORZI commercialization - Stock Titan
Coherus Oncology (NASDAQ:CHRS) Stock Price Crosses Above 200 Day Moving AverageShould You Sell? - MarketBeat
Coherus Oncology Enters Clinical Supply Agreement with Johnson & Johnson for Combination Cancer Therapy Study - Global Legal Chronicle
Coherus Oncology announces deal with J&J - The Pharma Letter
Johnson & Johnson (JNJ) Partners with Coherus (CHRS) for Cancer Therapy Trial - GuruFocus
Coherus Oncology Inc announces agreement with JanssenSEC filing - marketscreener.com
Coherus Signs Clinical Supply Deal With Janssen Oncology - TipRanks
Coherus Oncology IncAnnounces Agreement With JanssenSEC Filing - TradingView
Coherus Oncology Announces Clinical Supply Agreement with Janssen - TradingView
Coherus Oncology (NASDAQ:CHRS) Share Price Crosses Above 200-Day Moving AverageWhat's Next? - MarketBeat
Registration-Ready: How 2026’s Clinical Leaders Are Beating Cancer Benchmarks - Cantech Letter
Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks - Newswire Canada
Coherus Oncology (CHRS) Taps ATM Facility: Strategic Lifeline or Dilution Trade-Off for Its Pipeline? - simplywall.st
Coherus Oncology (CHRS) Is Up 28.7% After ATM Offering And Bullish CoverageWhat's Changed - Yahoo Finance
Coherus Oncology Surges 30% Following Oppenheimer’s Outperform Rating - timothysykes.com
Coherus Oncology a new outperform at Oppenheimer on tagmokitug potential - MSN
Coherus BioSciences Shares Surge on Analyst Initiation and Capital Move - AD HOC NEWS
Coherus Oncology Stock Surges Following Analyst Ratings and Clinical Developments - timothysykes.com
Improved Revenues Required Before Coherus Oncology, Inc. (NASDAQ:CHRS) Stock's 54% Jump Looks Justified - 富途牛牛
Investors Purchase Large Volume of Coherus Oncology Call Options (NASDAQ:CHRS) - Defense World
Coherus Oncology files prospectus to offer up to $64.9 million in stock - Investing.com Nigeria
Coherus Biosciences Updates ATM Equity Offering Program - TipRanks
Coherus Oncology Files Prospectus Supplement for Stock Offering - TradingView
Oppenheimer Initiates Coherus Oncology (CHRS) at Outperform with $10 Price Target - Intellectia AI
Coherus Oncology (CHRS) Set for Major Upside with Promising Canc - GuruFocus
Coherus Oncology a new outperform at Oppenheimer on tagmokitug potential ( - Seeking Alpha
Coherus Oncology Sees Unusually Large Options Volume (NASDAQ:CHRS) - MarketBeat
Coherus Oncology stock soars 35% after Oppenheimer initiates with massive upside - Investing.com Canada
Oppenheimer Maintains Coherus Oncology(CHRS.US) With Buy Rating, Maintains Target Price $10 - 富途牛牛
Oppenheimer Initiates Coverage on Coherus BioSciences With Outperform Rating - marketscreener.com
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Oppenheimer Initiates Coverage of Coherus Oncology (CHRS) with Outperform Recommendation - Nasdaq
Biotech Stocks Surge: Coherus Up 9.09% in After-Hours Trading - intellectia.ai
Coherus Oncology, Inc. (NASDAQ:CHRS) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Oppenheimer initiates Coherus Biosciences stock with Outperform rating By Investing.com - Investing.com Canada
Oppenheimer initiates Coherus Biosciences stock with Outperform rating - Investing.com
Coherus Oncology (NASDAQ:CHRS) Share Price Passes Above 200-Day Moving AverageHere's Why - MarketBeat
Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference - 富途资讯
Coherus Oncology Inc Stock (CHRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):